Impact of COVID-19 in AChR Myasthenia Gravis and the Safety of Vaccines: Data from an Italian Cohort

Background and aims. Patients with Myasthenia gravis (MG) are considered vulnerable as they may present with respiratory muscle weakness and because they are on immunosuppressive treatment; thereby, COVID-19 may have a detrimental effect on these patients. Vaccines against COVID-19 are currently ava...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Antonino Lupica, Vincenzo Di Stefano, Salvatore Iacono, Antonia Pignolo, Martina Quartana, Andrea Gagliardo, Brigida Fierro, Filippo Brighina
Format:	Artigo
Jezik:	Inglês
Izdano:	MDPI AG 2022-04-01
Serija:	Neurology International
Teme:	COVID-19 SARS-CoV2 vaccine Myasthenia gravis neuromuscular myasthenic crisis
Online dostop:	https://www.mdpi.com/2035-8377/14/2/33
Oznake:	Označite Brez oznak, prvi označite!